查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1510434

长 QT 症候群治疗市场 - 按类型（1 型、2 型、3 型）、治疗（药物、手术）、诊断（测试、心电图、基因测试）、全球预测（2024 年 - 2032 年）

Long QT Syndrome Treatment Market - By Type (Type 1, Type 2, Type 3), Treatment (Medication, Surgical Procedures), Diagnosis (Tests, Electrocardiogram, Genetic Testing), Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3个工作天内

价格
简介目录

在该领域领先公司加大研发力度的推动下，2024 年至 2032 年间，全球长 QT 症候群治疗市场的复合年增长率将达到 6.8%。长 QT 症候群是一种以心律异常为特征的心臟疾病，需要专门治疗以预防危及生命的心律不整。该公司正在投资创新疗法，例如新药物配方和先进医疗设备，以满足长 QT 综合征患者的特定需求。

例如，2023 年 8 月，Thryv Therapeutics Inc. 宣布了 WAVE 1 概念验证临床试验的令人鼓舞的结果，该试验评估了 LQT-1213 对于减少多非利特诱导的长 QT 个体的 QTcF 的作用。 LQT-1213 是一种强大的选择性血清糖皮质激素诱导激酶 1 (SGK-1) 抑制剂，SGK-1 是与 QTc 延长相关的因素。

此外，人们越来越关注基因检测，以确定与疾病相关的潜在基因突变。随着对长 QT 综合征分子基础了解的进步和标靶治疗的发展，对有效治疗的需求不断增加，为改善患者治疗结果带来了希望。

长QT综合征治疗行业的整体规模根据类型、治疗、诊断和地区进行分类。

从2024 年到2032 年，2 型长QT 症候群将呈现出令人称道的增长。的治疗。这种亚型的患者面临更高的危及生命的心律不整的风险，需要进行标靶治疗。随着研究的不断进展，人们对 2 型长 QT 症候群的分子机制有了越来越多的了解，从而开发出适合其特定需求的更有效的治疗方法。这导致长 QT 综合症治疗市场对专门疗法的需求不断增长。

基因检测领域的长QT 症候群治疗市场将在2024 年至2032 年实现显着的复合年增长率。策略。基因测试可以识别这些突变，从而为患者提供标靶治疗和风险分层。随着新一代定序等基因检测技术的进步，导致长 QT 症候群的突变的识别变得更加容易和准确。因此，长 QT 综合征治疗市场对基因检测的需求不断增长，从而促进了更精确和客製化的患者护理方法。

欧洲长QT 症候群治疗市场将在2024 年至2032 年呈现可观的复合年增长率。和诊断。以个人化医疗为重点，欧洲医疗保健提供者正在采用创新疗法和基因检测，为个别患者量身定制治疗方案。随着医疗保健系统努力改善长 QT 综合征患者的治疗结果，这导致欧洲对长 QT 综合征治疗的需求不断增长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 长 QT 症候群的盛行率不断上升
      • 治疗方式的技术进步
      • 基因检测和诊断的进步
      • 老年人口不断增加
    • 产业陷阱与挑战
      • 手术费用高
  • 成长潜力分析
  • 监管环境
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 1 型长 QT 症候群
  • 2 型长 QT 症候群
  • 长 QT 症候群 3 型
  • 其他类型

第 6 章：市场估计与预测：按处理方式，2021 - 2032 年

  • 主要趋势
  • 药物
    • 依药物类型
      • 钾补充剂
      • β-受体阻断剂
      • 钠通道阻断剂
    • 按配销通路
      • 医院药房
      • 零售药局
      • 网路药局
  • 外科手术
    • 按程式类型
      • 植入式心律转復除颤器 (ICD) 放置
      • 左心交感神经去神经术（LCSD）
      • 心臟移植
    • 按最终用途
      • 医院
      • 心臟中心
      • 其他最终用户

第 7 章：市场估计与预测：按诊断 2021 - 2032

  • 主要趋势
  • 测试
  • 心电图
  • 基因检测
  • 其他诊断类型

第 8 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 中东和非洲其他地区

第 9 章：公司简介

  • Abbott Laboratories
  • AstraZeneca
  • Bayer AG
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Bristol Myers Squibb
  • GSK plc
  • Medtronic Plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
简介目录
Product Code: 8775

Global Long QT Syndrome Treatment Market will witness 6.8% CAGR between 2024 and 2032, driven by increased research and development efforts by leading companies in the field. Long QT Syndrome is a cardiac disorder characterized by abnormal heart rhythms, necessitating specialized treatment to prevent life-threatening arrhythmias. Companies are investing in innovative therapies, such as new drug formulations and advanced medical devices, to address the specific needs of Long QT Syndrome patients.

For instance, in August 2023, Thryv Therapeutics Inc. announced encouraging results from the WAVE 1 Proof of Concept clinical trial assessing LQT-1213 for reducing QTcF in individuals with long QT dofetilide-induced. LQT-1213 is a powerful and selective inhibitor of Serum Glucocorticoid-Inducible Kinase 1 (SGK-1), a factor associated with QTc prolongation.

Additionally, there is a growing focus on genetic testing to identify the underlying genetic mutations associated with the condition. With advancements in understanding the molecular basis of Long QT Syndrome and the development of targeted treatments, the demand for effective therapies is rising, offering hope for improved patient outcomes.

The overall Long QT Syndrome Treatment Industry size is classified based on type, treatment, diagnosis, and region.

The long QT syndrome type 2 segment will exhibit commendable growth from 2024 to 2032. Long QT Syndrome type 2, one of the subtypes of this cardiac disorder, requires specialized treatment due to its distinct genetic and physiological characteristics. Patients with this subtype face a higher risk of life-threatening arrhythmias, necessitating targeted therapies. As research continues to advance, there is a growing understanding of the molecular mechanisms underlying Long QT Syndrome type 2, leading to the development of more effective treatments tailored to its specific needs. This has resulted in a rising demand for specialized therapies in the Long QT Syndrome treatment market.

The long QT syndrome treatment market from the genetic testing segment will register a notable CAGR from 2024 to 2032. Long QT Syndrome, a genetic heart rhythm disorder, requires personalized treatment strategies based on the specific genetic mutations involved. Genetic testing allows for the identification of these mutations, enabling targeted therapies and risk stratification for patients. With advancements in genetic testing technologies, such as next-generation sequencing, the identification of Long QT Syndrome-causing mutations has become more accessible and accurate. As a result, there is a growing demand for genetic testing in the Long QT Syndrome treatment market, facilitating more precise and tailored approaches to patient care.

Europe long QT syndrome treatment market will demonstrate a decent CAGR from 2024 to 2032. European countries are increasingly investing in advanced healthcare systems, leading to greater awareness and diagnosis of rare conditions like Long QT Syndrome. With a focus on personalized medicine, European healthcare providers are adopting innovative therapies and genetic testing to tailor treatments to individual patients. This has resulted in a growing demand for Long QT Syndrome treatments in Europe as healthcare systems strive to improve outcomes for patients with this condition.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Growing prevalence of long QT syndrome
      • 3.2.1.2 Technological advancements in treatment modalities
      • 3.2.1.3 Advancement in genetic testing and diagnosis
      • 3.2.1.4 Growing geriatric population
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of surgical procedures
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Million)

  • 5.1 Key trends
  • 5.2 Long QT syndrome type 1
  • 5.3 Long QT syndrome type 2
  • 5.4 Long QT syndrome type 3
  • 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Treatment, 2021 - 2032 ($ Million)

  • 6.1 Key trends
  • 6.2 Medication
    • 6.2.1 By drug type
      • 6.2.1.1 Potassium supplements
      • 6.2.1.2 Beta-blockers
      • 6.2.1.3 Sodium channel blockers
    • 6.2.2 By distribution channel
      • 6.2.2.1 Hospital pharmacies
      • 6.2.2.2 Retail pharmacies
      • 6.2.2.3 Online pharmacies
  • 6.3 Surgical procedures
    • 6.3.1 By procedure type
      • 6.3.1.1 Implantable cardioverter-defibrillator (ICD) placement
      • 6.3.1.2 Left cardiac sympathetic denervation (LCSD)
      • 6.3.1.3 Cardiac transplantation
    • 6.3.2 By end-use
      • 6.3.2.1 Hospitals
      • 6.3.2.2 Cardiac centers
      • 6.3.2.3 Other end-users

Chapter 7 Market Estimates and Forecast, By Diagnosis 2021 - 2032 ($ Million)

  • 7.1 Key trends
  • 7.2 Tests
  • 7.3 Electrocardiogram
  • 7.4 Genetic testing
  • 7.5 Other diagnosis types

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 AstraZeneca
  • 9.3 Bayer AG
  • 9.4 Boehringer Ingelheim
  • 9.5 Boston Scientific Corporation
  • 9.6 Bristol Myers Squibb
  • 9.7 GSK plc
  • 9.8 Medtronic Plc
  • 9.9 Merck & Co., Inc.
  • 9.10 Pfizer Inc.
  • 9.11 Sanofi